Caffeic Acid Tablets as a Second-line Therapy for ITP

Status Completed

Clinical Trial Summary

The investigators are undertaking a multicentre, randomised controlled trial of 120 adults with newly diagnosed ITP from 5 medical centers in China. Part of the participants are randomly selected to receive caffeic acid tablets combining dexamethasone and the other part are selected to receive high-dose dexamethasone treatment. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.

Clinical Trial Description

All participants' platelet count will be monitored weekly. Response will be evaluated after 3, 6 and 12 months after treatment. If the participant did not get complete response or response after 3 months, he would quit the trail. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Immune Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic
Thrombocytopenia
Thrombocytosis

Clinical Trial Details

NCT number	NCT02351622
Study type	Interventional
Source	Shandong University
Contact
Status	Completed
Phase	Phase 3
Start date	September 2012
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02287649` - Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)	N/A
Terminated	`NCT02401061` - PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP	Phase 1/Phase 2
Completed	`NCT02868099` - Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)	Phase 3
Completed	`NCT02556814` - Caffeic Acid Combining High-dose Dexamethasone in Management of ITP	Phase 4
Active, not recruiting	`NCT04741139` - Post IVIG Medication in Children With Immune Thrombocytopenia	Phase 1
Not yet recruiting	`NCT05468866` - The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immune Thrombocytopenia	N/A
Not yet recruiting	`NCT05494307` - The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia	Phase 2
Recruiting	`NCT04993885` - Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies	Phase 2
Recruiting	`NCT05281068` - The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia	Phase 2
Not yet recruiting	`NCT05020288` - A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP	Phase 2
Withdrawn	`NCT03965624` - Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia	Phase 2
Not yet recruiting	`NCT03252457` - Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP	Phase 3
Recruiting	`NCT05937828` - OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Completed	`NCT03156452` - Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate	Phase 3
Completed	`NCT03164915` - A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)	Phase 3
Recruiting	`NCT02270801` - Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy	Phase 3
Withdrawn	`NCT01976195` - High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP	Phase 2
Completed	`NCT01933035` - Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.	N/A
Recruiting	`NCT02821572` - Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)
Not yet recruiting	`NCT05562882` - A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia	Early Phase 1